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Abstract
OBJECTIVE: To evaluate the efficacy and safety of
Xuefuzhuyu decoction for hyperlipidemia.
METHODS: Randomized clinical trials on hyperlip-
idemia treated by Xuefuzhuyu decoction, either
alone or with Western Medicine, were searched in
electronic databases. Databases searched were:
MEDLINE, Allied and Complementary Medicine Da-
tabase, EMBASE, The Cochrane Library 2013 (Issue
4), China National Knowledge Infrastructure Data-
base, Chinese Biomedical Literature Database, and
Wanfang Database up to 2 May, 2013. Study selec-
tion, data extraction, quality assessment, and data
analysis were conducted according to the Co-
chrane standards.
RESULTS: Six randomized clinical trials involving
748 patients (373 patients in the treatment group,
375 patients in the control group) were included in
the analysis. The studies were of low methodologi-
cal quality. Meta-analysis indicated that the effect
of Xuefuzhuyu decoction on hyperlipidemia was
better than that in the control group [n=748, OR=
5.07, 95% CI (3.40, 7.58), P<0.01]. Weighted mean
differences in total cholesterol, low-density lipopro-
tein cholesterol, triglycerides, and high-density li-
poprotein cholesterol were ﹣0.79, ﹣0.74, ﹣0.44,
0.16, respectively, and Meta-analysis revealed that
the treatment group was better than the control
group with 95% CI (﹣1.21,﹣0.36), (﹣0.94, ﹣0.55),
(﹣ 0.77, ﹣ 0.11), (0.04, 0.27), respectively (all P<
0.05). Some adverse events in evaluated studies
were recorded.
CONCLUSION: Xuefuzhuyu decoction may be ef-
fective for treating hyperlipidemia. The studies we
analyzed were of low methodological quality,
which indicates that the above findings should be
considered cautiously. Therefore, more strictly de-
signed large-scale randomized clinical trials are
needed to evaluate the efficacy of Xuefuzhuyu de-
coction in hyperlipidemia.
© 2014 JTCM. All rights reserved.
Key words: Hyperlipidemias; Medicine, Chinese tra-
ditional; Treatment outcome; Meta-analysis; Re-
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INTRODUCTION
Hyperlipidemia, including elevated serum total choles-
terol (TC) and low-density lipoprotein cholesterol
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(LDL-C), is an independent risk factor for atherosclero-
sis. It can lead to coronary heart disease and ischemic
stroke.1,2 The first phase of National Health and Nutri-
tion Examination Survey (NHANES Ⅲ) (1988-1991)
indicated that 49% of adult Americans have a TC≥
5.2 mmol/L (200 mg/dL).3 An update of NHANES Ⅲ
from 1999-2000 reported that adult Americans
age-standardized TC is 5.27 mmol/L (203 mg/dL).4
Therefore, prevention and treatment of hyperlipidemia
is very important. Common lipid-lowering drugs used
in clinic at present include Hydroxy methylglutaryl co-
enzyme A (HMG-CoA) reductase inhibitors (statins),
phenoxy aromatic acids (fibrates), nicotinic acid and its
derivatives, and other types of lipid-lowering drugs. All
of the main lipid-lowering drugs, such as statins and fi-
brates, have certain side effects. Moreover, the combi-
nation of statins and fibrates has a high risk of side ef-
fects such as muscle damage and liver damage.
More than 2000 plants are used in traditional herbal
or alternative medical systems and some may provide
relief to patients with cardiovascular diseases, especially
those with hyperlipidemia and ischemic heart disease.
In China, Japan, and other areas in Asia, the usage of
herbs is based on Traditional Chinese Medicine
(TCM) theory. Syndrome and disease differentiation
are important to TCM. Therefore, hyperlipidemia in
TCM is considered a blood stasis syndrome. Hyperlip-
idemia including hemodynamic changes and arterial
plaque caused by hyperlipidemia, should be treated by
activating blood and dissolving stasis.5 Xuefuzhuyu de-
coction, which originated in the Qing Dynasty, is con-
sidered one of the most effective decoctions for activat-
ing blood and dissolving stasis related to the cardiovas-
cular and cerebrovascular systems. The clinical use of
Xuefuzhuyu decoction may improve blood circulation,
and relieve the symptoms of angina or other cardiovas-
cular diseases.6 Some studies indicate that Xuefuzhuyu
decoction is effective on hyperlipidemia. Therefore, a
systematic review of clinical trials related to Xuefu-
zhuyu decoction and hyperlipidemia are reported in
this study.
MATERIALS ANDMETHODS
Inclusion criteria for studies
Randomized controlled trials (RCTs) or quasi-RCTs,
either in English or Chinese, regardless of journal, allo-
cation concealment, or blinding method, were includ-
ed in our analysis.
Inclusion and exclusion criteria for participants
Patients with hyperlipidemia were included regardless
of their age, sex, or race if the diagnosis of hyperlipid-
emia was made by "Screening and management of lip-
ids"7 or any other reasonable criteria. Patients with dia-
betes, hypothyroidism, nephrotic syndrome, liver and
gallbladder disease that could lead to secondary hyper-
lipidemia were excluded. Those with severe heart, liver,
or kidney disease, or severe infection were also exclud-
ed.
Primary and secondary outcomes
The primary outcome was lipid-lowering efficacy. Sec-
ondary outcomes were TC, LDL-C, triglyceride (TG),
and high-density lipoprotein cholesterol (HDL-C) lev-
els.
Outcome measurement
Efficacy evaluation criteria were determined according
to "Chinese Adult dyslipidemia Prevention Guide"8
and other guidelines. "Effective" was considered TC
decreased >10% , TG decreased >20% , or one of the
lipid indexes was restored to normal after intervention.
"Invalid" was considered TC decreased <10%, TG de-
creased <20% , or none of the lipid indexes were re-
stored to normal after intervention. "Worsened" was
considered when TC or TG increased >10%, or other
lipid indexes exceeded normal after intervention.
Literature search
The following electronic databases were searched since
the beginning of the database to 2 May, 2013: Medical
Literature Analysis and Retrieval System Online, Allied
and Complementary Medicine Database, Excerpta
Medica Database, The Cochrane Library 2013 (Issue
4), and three Chinese Databases: China National
Knowledge Infrastructure Database, Chinese Biomedi-
cal Literature Database, and Wanfang Database. The
search terms used were "Xuefuzhuyu", "lipid", "hyper-
lipidemia", "dyslipidemia", "hypercholesterolemia",
and "hypertriglyceridemia". Various combinations of
the search terms were used depending on the database.
The type of publication was clinical study. Two review-
ers (Weijiang Song and Weihan Zhao) worked inde-
pendently for inclusion of studies. Any disagreements
were resolved through discussion.
Data extraction and quality assessment
Articles were identified and selected independently by
two reviewers (Jiaxing Tian, Beijing University of Chi-
nese Medicine, and Tengfei Li, Beijing Hospital of Tra-
ditional Chinese Medicine, both of them had been
trained in Beijing University of Chinese Medicine for
identifying and selecting the articles) according to the
established inclusion criteria. The methodological qual-
ity was assessed via the Cochrane Collaboration's risk
of bias criteria:9 (a) whether the random method is cor-
rect; (b) whether allocation concealment is used; (c)
whether the blind method is used; and (d) whether lost
cases are described and intent-to-treat analysis is used.
If all the above quality standards were "adequate," it
was unlikely that there would be any biases. However,
if one criterion was "not clear," there was a moderate
probability of corresponding bias. If one criterion was
"inadequate" or "not used," there was a high probabili-
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ty of corresponding bias. Discrepancies were resolved
by consensus through discussion between the two re-
viewers and, if needed, by asking for further evaluation
from the other two reviewers (Jiangquan Liao, Beijing
University of Chinese Medicine, and Jinhang Du, Chi-
na-Japan Friendship Hospital).10
Statistical analysis
The mean changes in TC, LDL-C, TG, and HDL-C
compared with baseline were calculated in the Xuefu-
zhuyu decoction and control arms. These changes were
used to assess the differences between the intervention
and control groups. The odd risk (OR) of data was cal-
culated if the variables were dichotomous data. The
weighted mean difference (WMD) was calculated if the
variables were continuous data. A 95% confidence in-
terval (CI) was also calculated from the data using the
Cochrane Collaboration's software.11
RESULTS
Study description
A total of 105 articles were identified. After screening
the titles and abstracts,26 potentially relevant studies
were found. After detailed evaluation of the full text,20
some articles were excluded. Most articles were exclud-
ed because hyperlipidemia was only a complication, or
lipids were not the main evaluating indexes. One arti-
cle was excluded because it claimed that it was a RCT,
but was actually a cohort study using healthy people
without intervention as the control group. One article
was excluded because it only reported differences be-
tween the treatment and control groups after treat-
ment. Eventually, six articles met our inclusion criteria
(Figure 1). All studies were RCTs from China. Three14,16,17
of the included trials used Xuefuzhuyu decoction plus
simvastatin as the treatment group and simvastatin as
the control group. Two studies12,13 used Xuefuzhuyu de-
coction alone as treatment and inositol nicotinate tab-
lets as the control group. One trial15 used Xuefuzhuyu
decoction alone as the treatment group and Xuezhi-
kang capsule (a Chinese patent medicine extracted
from red yeast rice which can reduce lipids) as the con-
trol group. Detailed data of all the included research
are summarized in Table 1.
Quality assessment
All studies mentioned randomization but none de-
scribed detailed randomization methods. Five showed
no significant differences in baseline. None mentioned
allocation concealment, blinding methods, or inten-
tion-to-treat. Therefore, all six studies had high proba-
bilities of selection bias, performance bias, or measure-
ment bias (Table 2).
Efficacy evaluation
All six studies12-17 compared efficacy between the treat-
ment group and the control group after intervention.
The treatment group scored significantly higher than
the control group [n=748, OR=5.07, 95% CI (3.40,
7.58), P<0.01]. Three14,16,17 of the studies used Xuefu-
zhuyu decoction plus unspecified lipid-lowering drugs
as the treatment group while three12,13,15 used Xuefu-
zhuyu decoction alone as treatment. All of the sub-
groups showed that the treatment group was more ef-
fective than the control group [n=401, OR=5.49, 95%
CI (3.02, 9.98), P<0.01 and n=347, OR=4.74, 95%
CI (2.76, 8.14), P<0.01]. The efficacy evaluation in
two studies12,13 is different from other studies. "Effec-
tive" should be classified until one or more lipid index-
es reached normal.12,13 Compared with other included
studies, this might lead to false "invalid" findings. The
total outcome did not interfere with the results after ex-
cluding the two studes12,13 because the treatment group
still scored higher than the control group [n=579, OR=
5.48, 95% CI (3.43, 8.75), P<0.01] (Figure 2).
In the subgroup Xuefuzhuyu decoction plus lipid-low-
ering drugs, Xuefuzhuyu decoction was combined with
conventional lipid-lowering drugs in the treatment
group compared with only conventional lipid-lowering
drugs in the control group. In the subgroup Xuefu-
zhuyu decoction alone, Xuefuzhuyu decoction was
used alone in the treatment group compared with con-
ventional lipid-lowering drugs in the control group.
Index evaluation
Four studies14-17 compared the effect of lowering TC be-
tween the treatment and control groups. The treat-
ment group was significantly more effective than the
control group [n=439, WMD=﹣0.79, 95% CI (﹣1.21,
﹣ 0.36)]. Both of the subgroups, Xuefuzhuyu decoc-
tion plus lipid-lowering drugs and Xuefuzhuyu decoc-Figure 1 Flow chart of trial selection process
Initially identified publications (n=105)
Publications excluded through screening
the title and abstract (n=76)·Not relevant to hyperlipidemia (n=28)·Not clinical trial (n=48)
Articles further evaluated by full text (n=26)
Excluded publications after reading the
full text (n=20)·Hyperlipidemia is only a complication
or lipids is not the main evaluating index
(n=15)·Lack of detailed data (n=1)·Case reports or cohort study (n=4)
Researches included in the systematic review (n=6)
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tion alone, showed effectiveness in lowering TC [n=
275, WMD=﹣0.85, 95% CI (﹣1.35,﹣0.34) and n=
164, WMD=﹣0.57, 95% CI (﹣0.98, ﹣0.16)]. The
differences exist in the test for subgroups differences
(P<0.05 but P>0.01). In these four studies, only one14
did not apply syndrome differentiation on the includ-
ed patients to adjust the usage of herbal medicines.
However, the patients were regarded as having blood
stasis because the inclusion criteria included blood sta-
sis. Additionally, the usage of Xuefuzhuyu decoction in
one14 study was based on syndrome differentiation.
Both the Xuefuzhuyu decoction plus lipid-lowering
drugs and the Xuefuzhuyu decoction alone were more
effective than the control groups for lowering TC (Fig-
ure 3).
Only two studies14,16 recorded a comparison of LDL-C
between the treatment group and the control group af-
ter intervention. The treatment group was significantly
more effective than the control group in lowering
LDL-C [n=158, WMD=﹣ 0.74, 95% CI (﹣ 0.94,
﹣0.55)]. Both of the studies used Xuefuzhuyu decoc-
tion plus simvastatin as treatment group and simvas-
tatin alone as control group. One16 study used syn-
drome differentiation and added certain herbal medi-
cines based on the differentiation. One other study14 also
used differentiation. However, one14 was not as effective
as the other16 (WMD=﹣0.57, 95% CI (﹣1.09,﹣0.05)]
vs [WMD=﹣0.77, 95%CI (﹣0.98,﹣0.56)], and statis-
tically the heterogeneity was low (P>0.05). This indi-
cates that the confidence of the data integration was
valid, and Xuefuzhuyu decoction plus simvastatin is
more effective than simvastatin alone in lowering
LDL-C (Figure 4).
Four studies14-17 compared the effect of lowering TG be-
tween the treatment group and the control group. The
treatment group was significantly more effective than the
control group in lowering TG [n=439, WMD=﹣0.40,
95% CI (﹣ 0.59, ﹣ 0.20)]. In the subgroup Xuefu-
zhuyu decoction plus lipid-lowering drugs as treat-
ment, one14 study did not show a significant difference
in lowering TG between the treatment and control
groups. However, meta-analysis showed that Xuefu-
zhuyu decoction plus lipid-lowering drugs was more ef-
fective than lipid-lowering drugs in lowering TG (het-
erogeneity: P>0.05). All three studies14,16,17 in the sub-
group Xuefuzhuyu decoction plus lipid-lowering drugs
used simvastatin as the conventional lipid-lowering
drug. Simvastatin usually lowers TC and LDL-C. Us-
ing TG-lowering drugs like fenofibrate could enhance
the investigation of Xuefuzhuyu decoction for TG-low-
ering effectiveness. However, hyperlipidemia is always
a combination of varying degrees of hypercholesterol-
emia and hypertriglyceridemia, and the combination
of statins and fibrates could increase the chances side ef-
fects. Therefore, the lowering of TG after combination
of Xuefuzhuyu decoction and simvastatin indicates
that Xuefuzhuyu decoction could be an adjuvant or re-
placement therapy for hyperlipidemia.Tab
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The subgroup that used Xuefuzhuyu decoction alone
as treatment group, used Xuezhikang capsule as a con-
trol group. Xuezhikang capsule is a Chinese patent
medicine mainly extracted from red yeast rice. Clinical
trials and experimental research has shown that Xuezhi-
kang capsule has certain lipid-lowering effects.18,19 One
study15 used syndrome differentiation, and showed that
Xuefuzhuyu decoction alone was more effective than
Xuezhikang capsule at lowering TG [n=164, WMD=
﹣0.88, 95% CI (﹣1.51, ﹣0.25)]. This indicates the
importance of syndrome differentiation (Figure 5).
Four studies14-17 compared the effect on increasing
HDL-C between the treatment group and the control
group. The treatment group was more effective than
the control group in significantly increasing HDL-C
[n=439, WMD=0.16, 95% CI (0.04, 0.27)]. Three-
studies14,16,17 used Xuefuzhuyu decoction plus lipid-low-
ering drugs as a treatment group, while one15 used Xue-
fuzhuyu decoction alone as a treatment group. The for-
mer subgroup showed that there was no statistical dif-
ference between the treatment group and the control
group [n=275, WMD=0.15, 95% CI (﹣0.04, 0.34)].
However, there was tendency for Xuefuzhuyu decoc-
tion plus lipid-lowering drugs to exceed lipid-lowering
drugs in increasing HDL-C. After data integration of
both subgroups, the difference is statistically significant
(Figure 6).
Security
Two14,16of all studies listed safety reports. Both studies
used Xuefuzhuyu decoction plus lipid-lowering drugs
in the treatment group. In the treatment group, four
Study
Hong B et al
200012
Tian YF
200113
Lei WN
200614
Wang XY
200915
Zeng XG
201116
Qiu J 201217
Random
sequence
generation
NMT
NMT
NMT
NMT
NMT
NMT
Allocation
concealment
NMT
NMT
NMT
NMT
NMT
NMT
Blinding of
participants, personnel
and outcome assessors
NMT
NMT
NMT
NMT
NMT
NMT
Incomplete
outcome data
NMT
NMT
NMT
NMT
Mentioned
NMT
Selective
report bias
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Other
sources of
bias
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Grade of
risk of bias
Ca
Ca
Ca
Ca
Ca
Ca
Table 2 Quality assessment of evaluated studies
Notes: NMT: not mentioned. aHigh probability of occurrence of the corresponding bias.
Figure 2 Meta-analysis of efficacy
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out of 79 patients who received Xuefuzhuyu decoction
plus simvastatin had gastrointestinal discomfort, one
had fatigue, and one had headache and dizziness. In
the control group, 79 patients received simvastatin,
and 15 had gastrointestinal discomfort, 12 had head-
ache and dizziness, and one had fatigue.
Follow-up
None of these RCTs included follow-up.
DISCUSSION
Based on the results, Xuefuzhuyu decoction may be
able to treat hyperlipidemia with no significant side ef-
fects. However, all of the studies in this review had low
methodology quality and the sample sizes were small.
These studies lacked the details of randomization, allo-
cation concealment, and blinding methods, which lead
to inability to judge whether the study was conducted
properly. There were no multi-center or large-scale ran-
Figure 5 Meta-analysis of TG
TG: triglyceride. Xuefuzhuyu decoction group vs control group, it shown significant effect in lowering TG.
Figure 3 Meta-analysis of TC
TC: total cholesterol. Both the test for overall and subgroups indicated that treatment group was better than control group.
Figure 4 Meta-analysis of LDL-C
LDL-C: low-density lipoprotein cholesterol.
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domized clinical trials about Xuefuzhuyu decoction in
treating hyperlipidemia. Therefore, the use of Xuefu-
zhuyu decoction for hyperlipidemia is not adequate.
According to this systematic review, Xuefuzhuyu decoc-
tion could enhance the effectiveness of lipid-lowering
drugs. Moreover, Xuefuzhuyu decoction showed effec-
tiveness in lowering TG, which provides more flexible
choices in treatment protocols for hyperlipidemia. The
application of syndrome differentiation based on TCM
theory is very important in the usage of Chinese herbal
medicines. According to this systematic review, Xuefu-
zhuyu decoction could be used in hyperlipidemia pa-
tients with different syndromes based on the guidance
of accurate differentiation. The methodological quality
of these clinical trials for Xuefuzhuyu decoction should
be improved. Evaluating the efficacy of Xuefuzhuyu de-
coction on hyperlipidemia requires more strictly de-
signed large-scale randomized clinical trials.
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